Post-stroke cognitive impairment

A newly published review titled “Recognizing, managing, and preventing cognitive sequelae after stroke. A narrative review”.
highlights the growing clinical relevance of post-stroke cognitive impairment (PSCI). The main authors are Prof. Leonardo Pantoni and Prof. Michael Brainin, leading experts in cerebrovascular disease research and post-stroke cognitive impairment.

PSCI affects approximately one-third of all stroke survivors and is a major contributor to long-term disability and reduced quality of life. Its incidence increases with stroke severity.

PSCI presents as a heterogeneous syndrome, most commonly involving deficits in attention and executive function.

The authors emphasize that diagnosis remains challenging in routine clinical practice. A structured, stepwise approach combining cognitive screening, detailed neuropsychological assessment, and neuroimaging is recommended to adequately identify cognitive impairment after stroke.

Current treatment options remain limited and focus mainly on non-pharmacological interventions such as cognitive rehabilitation and physical activity.

Could Cerebrolysin^® be part of the solution?

The review also points to emerging pharmacological approaches in PSCI. Cerebrolysin^® has shown promising results in real-world evidence from the CREGS study and is currently being further investigated in the randomized trial.

Stay tuned for upcoming insights!